Capital Gain

Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals

Published: (Updated: ) in FINTECH, , , , , , , , , , , , , , , , , , by . Leave a Comment on Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals.

Johnson & Johnson’s single-dose COVID-19 vaccine is 66% effective, lagging rivals | Fortune You need to enable JavaScript to view this site. Source link